Diabetes Mellitus, Type 1 study: Baricitinib
Official title A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
ClinicalTrials.gov ID: NCT07222137
What this study is testing
What is Baricitinib?
Baricitinib is an investigational oral medicine being studied for its potential to delay the onset of type 1 diabetes in people at high risk.
Also referred to as LY3009104.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to see whether baricitinib can postpone the onset of clinical type 1 diabetes in high‑risk individuals.
- Who it's for
- People who are at high risk of developing type 1 diabetes.
- What's involved
- Participants will receive baricitinib and have regular visits and tests to monitor diabetes development.
- Time commitment
- The study lasts up to about 5 years with periodic visits and tests.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 1 to 35
You may be able to join if
- Have a history of at least one documented occasion of at least two diabetes-related autoantibodies, AND one occasion of at least two diabetes-related...
- Have Stage 1b or Stage 2 type 1 diabetes
- Have a body weight of ≥8 kilograms (kg) (18 pounds) at screening
You likely can't join if
- Have any other type of diabetes
- Have uncontrolled high blood pressure
- Have had a heart attack, heart disease, stroke, or heart failure
- Have a history or high risk of venous thromboembolism, lymphoproliferative disease or malignancy
- Have a current or recent clinically serious infection
The study team makes the final eligibility decision.
Where it is enrolling
- Tallahassee, Florida, United States
- Iowa City, Iowa, United States
- West Des Moines, Iowa, United States
- Louisville, Kentucky, United States
- Charlottesville, Virginia, United States
- Adelaide, Australia
- Box Hill, Australia
- Brisbane, Australia
- Melbourne, Australia
- Parkville, Australia
- Perth, Australia
- Randwick, Australia
- Westmead, Australia
- Brussels, Belgium
- Edegem, Belgium
- Leuven, Belgium
- Namur, Belgium
- Belo Horizonte, Brazil
- Curitiba, Brazil
- Fortaleza, Brazil
+ 61 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 1 year to 35 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Tallahassee, Florida, United States; Iowa City, Iowa, United States; West Des Moines, Iowa, United States; Louisville, Kentucky, United States; Charlottesville, Virginia, United States; Adelaide, Australia and 75 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.